Wire · opportunities
Curium™ announces FDA approval of BEXLUTRY lutetium Lu 177 dotatate injection for ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 15 September 2026 · Fusion42 review
The FDA approved Curium's BEXLUTRY lutetium Lu 177 dotatate injection for treating adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, marking Curium's entry into oncology therapeutics with a vertically integrated radioligand therapy.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it.
◆ ◆ The Wire takeaway
You are facing a new competitor that controls both manufacturing and supply of a radioligand therapy for neuroendocrine tumors, taking advantage of FDA nod to scale treatment access. Planning how to collaborate or differentiate quickly could decide your market share before the launch momentum builds.
◆ Coverage
3 sources · 15 Sep 2026
◆ Related on Wire
◆ Topics